AZD1208AZD1208 is a novel, orally bioavailable, highly selective PIM kinases inhibitor with single nanomolar potency against all three PIM kinases and is currently undergoing Phase I testing and dose escalation studies in AML.
IC50 Value: < 5 nM
Target: pan-Pim kinase
AZD1208 suppresses the growth of MOLM 16 and KG 1 xenograft tumors in vivo in a dosedependent manner.